Why did aducanumab get approved?
Aducanumab clears out clumps of a protein in the brain called amyloid-β, which some researchers think is the root cause of Alzheimer’s. This theory is known as the amyloid hypothesis. The FDA approved the drug on the basis of its ability to reduce the levels of these plaques in the brain.
Is Biogen Alzheimer drug approved?
The US Food and Drug Administration (FDA) approved Biogen’s monoclonal antibody aducanumab (Aduhelm) on June 7 for early stage Alzheimer’s disease—the first new therapy approved for the neurogenerative disorder in nearly two decades.
Why did the FDA approve Alzheimer’s drug?
The accelerated approval of aducanumab established a precedent for others to follow. The FDA can approve Alzheimer’s drugs on the basis of their ability to remove amyloid-β from the brain — without clear evidence of cognitive benefit.
Why did FDA approve Biogen?
STAT News and other media outlets reported FDA officials used a regulatory shortcut to gain approval in order to get the drug on the market sooner. Biogen’s drug targets a “sticky” compound in the brain known as beta-amyloid, which scientists expect plays a role in the devastating disease.
Does Medicare cover aducanumab?
An estimated 80 percent of the patients eligible for aducanumab are covered by Medicare. To establish a consistent nation-wide policy, CMS launched a National Coverage Determination for aducanumab July 12 (CMS announcement; Endpoints News).
What class of drug is aducanumab?
It is used to treat people with mild cognitive impairment (MCI) or mild dementia. Aducanumab-avwa injection is in a class of medications called monoclonal antibodies. It works by blocking the formation of amyloid beta in the brain.
Why did Biogen’s shares fall after approval?
Biogen shares fell on Friday after the head of the Food and Drug Administration called for an investigation into the recent approval of the company’s Alzheimer’s drug, Aduhelm.
What is the FDA inspector general’s investigation into Biogen?
Acting FDA Commissioner Dr. Janet Woodcock asked the Office of the Inspector General to investigate interactions between the U.S. agency and Biogen representatives prior to the drug’s approval on June 7.
What does bibiogen’s latest setback mean for the drug?
Biogen’s drug targets a “sticky” compound in the brain known as beta-amyloid, which scientists expect plays a role in the devastating disease. It’s rare for an FDA chief to call for an investigation into the agency’s own decisions. It’s the latest setback for the company and the drug, which has been controversial since it showed promise in 2016.
Did FDA take a shortcut to get Biogen’s new brain drug approved?
STAT News and other media outlets reported FDA officials used a regulatory shortcut to gain approval in order to get the drug on the market sooner. Biogen’s drug targets a “sticky” compound in the brain known as beta-amyloid, which scientists expect plays a role in the devastating disease.